Simrone Pharmaceutical Industries Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 26-06-2024
- Paid Up Capital ₹ 0.90 M
as on 26-06-2024
- Company Age 33 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 4.90 Cr
as on 26-06-2024
- Revenue %
(FY 2022)
- Profit 6.06%
(FY 2022)
- Ebitda 6.06%
(FY 2022)
- Net Worth -10.65%
(FY 2022)
- Total Assets -4.95%
(FY 2022)
About Simrone Pharmaceutical Industries
- CIN/LLPIN
U24139MH1991PLC062545
- Company No.
062545
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Jul 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Simrone Pharmaceutical Industries?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sinhue Noronha  | Managing Director | 18-Jul-1991 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Simrone Noronha | Director | 20-Aug-2012 | Current |
| Susan Noronha | Director | 20-Aug-2012 | Current |
Financial Performance of Simrone Pharmaceutical Industries.
Simrone Pharmaceutical Industries Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 6.06% increase in profit. The company's net worth observed a substantial decline by a decrease of 10.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Simrone Pharmaceutical Industries?
In 2023, Simrone Pharmaceutical Industries had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATELIMITED.webp)
Africure Pharmaceuticals (India) Private LimitedActive 7 years 10 monthsSusan Noronha is a mutual person
Vs3 Golden Years Private LimitedActive 4 years 2 monthsSimrone Noronha, Susan Noronha and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dena Bank Creation Date: 19 Jun 1997 | ₹7.50 M | Satisfied |
Dena Bank Creation Date: 04 Jun 1997 | ₹3.70 Cr | Satisfied |
Maharashtra Apex Corporation Ltd. Creation Date: 15 Apr 1994 | ₹2.00 M | Satisfied |
How Many Employees Work at Simrone Pharmaceutical Industries?
Unlock and access historical data on people associated with Simrone Pharmaceutical Industries, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Simrone Pharmaceutical Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Simrone Pharmaceutical Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
